Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis.
Although dysphagia in patients with psptic stricture is attributed to a decreased luminal diameter, coexistent esophagitis may be an equally important cause.
The goals of this study were to determine whether medical healing of esophagitis in patients with stricture improves dysphagia and decreases dilatation need and to compare the efficacy and cost-effectiveness of omeprazole versus H2-receptor antagonists (H2RA).
Thirty-four dysphagic patients with peptic stricture and erosive esophagitis were dilated and randomized to omeprazole 20 mg every day versus H2RA (ranitidine 150 mg twice daily or famotidine 20 mg twice daily).
Patients received further dilatations only if dysphagia frequency was greater than or equal to once per week.
Mots-clés Pascal : Oesophagite, Homme, Traitement, Chimiothérapie, Etude comparative, Oméprazole, Sténose, Oesophage, Famotidine, Ranitidine, Antagoniste, Récepteur histaminergique H2, Analyse coût efficacité, Economie santé, Appareil digestif pathologie, Oesophage pathologie
Mots-clés Pascal anglais : Esophagitis, Human, Treatment, Chemotherapy, Comparative study, Stenosis, Esophagus, Antagonist, H2 receptor, Cost efficiency analysis, Health economy, Digestive diseases, Esophageal disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0494660
Code Inist : 002B02H. Création : 199501.